FGP
CORT icon

Freestone Grove Partners’s Corcept Therapeutics CORT Stock Holding History

Freestone Grove Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.5K Buy
995
+993
+49,650% +$60K ﹤0.01% 850
2026
Q1 		$81 Buy
+2
New +$75 ﹤0.01% 909

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's CORT Position: Q2 2026 in Review

Freestone Grove Partners increased its Corcept Therapeutics (CORT) stake by 49,650% in Q2 2026, buying an estimated $60K and bringing the position to 995 shares worth $86.5K. The position accounts for ﹤0.01% of the portfolio, ranked #850.

Freestone Grove Partners first reported a position in CORT in Q1 2026 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Freestone Grove Partners held 995 shares of Corcept Therapeutics worth $86.5K as of Q2 2026.
  • Freestone Grove Partners bought 993 Corcept Therapeutics shares in Q2 2026, an estimated $60K.
  • Corcept Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #850 holding.
  • Freestone Grove Partners first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.